^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    UBE2C (Ubiquitin Conjugating Enzyme E2 C)

    i
    Other names: UBE2C, Ubiquitin Conjugating Enzyme E2 C, UBCH10
    Associations

    News

    Trials
    7d
    KDM5C-regulated SIX5 promotes glioblastoma progression through transcriptional activation of UBE2C and enhancement of the Warburg effect. (PubMed, Front Immunol)
    In conclusion, SIX5 functions as a critical oncogenic driver in GBM, regulated by KDM5C and promoting tumor progression through UBE2C-mediated activation of AKT/mTOR signaling and glycolytic reprogramming. The KDM5C-SIX5-UBE2C regulatory axis represents a potential prognostic biomarker and therapeutic target in glioblastoma.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • KDM5C (Lysine Demethylase 5C) • PGK1 (Phosphoglycerate Kinase 1) • SLC2A1 (Solute Carrier Family 2 Member 1) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    7d
    Spatial confinement-enhanced CHA system based on tetrahedral DNA nanostructures for sensitive in situ mRNA analysis. (PubMed, Talanta)
    Furthermore, by modifying the recognition sequence, T-CHA achieved highly sensitive detection of miR-21, demonstrating the modular adaptability of the platform for different RNA targets as an initial proof of concept. By combining the structural precision of TDN with the signal amplification of CHA, T-CHA provides a robust and precise platform for the molecular diagnosis of HCC, highlighting its potential for further development toward diagnostic applications.
    Journal
    |
    MIR21 (MicroRNA 21) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    9d
    Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms. (PubMed, Drugs R D)
    The novel arylpiperazine derivative NAF19 exerts multi-targeted antitumor effects by concurrently inhibiting AR/AR-Vs signaling pathways and activating apoptotic cascades, thereby potently suppressing the migratory, invasive, and proliferative capacities of prostate cancer cells.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    |
    AR splice variant 7
    12d
    Integrating spatial and single-cell transcriptomics analysis reveals MYCN-UBE2C-TFRC signaling endows ferroptosis resistance in neuroectodermal tumors. (PubMed, Sci China Life Sci)
    Clinically, genetic silencing of UBE2C induces ferroptosis and sensitizes tumor cells to the ferroptosis inducer erastin, revealing a therapeutically exploitable vulnerability in MYCN-amplified malignancies. Our study reveals a previously unrecognized MYCN-UBE2C-TFRC-ferroptosis regulatory axis that drives neuroectodermal tumor growth. These findings establish a mechanistic rationale for combining UBE2C silencing and ferroptosis induction as a precision therapeutic strategy against MYCN-amplified tumors.
    Journal
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    |
    MYCN amplification
    |
    erastin
    1m
    Integrated multi-omics profiling to dissect the development of second primary lung cancer in laryngeal cancer: An observational study. (PubMed, Medicine (Baltimore))
    Additionally, immune cell infiltration analysis using CIBERSORT revealed a higher proportion of macrophages in both cancer types compared to non-tumor tissues. In conclusion, our study suggests that shared genetic alterations, regulated by specific TFs and miRNAs, alongside an altered immune microenvironment and CXCL12-mediated inositol phosphate metabolism likely driven by intermediate monocytes, contribute to the development of SPLC following laryngeal cancer.
    Observational data • Journal
    |
    RAD51 (RAD51 Homolog A) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • EDNRB (Endothelin Receptor Type B) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    1m
    UBE2C-orchestrated ubiquitination networks in cancer progression and therapy resistance. (PubMed, Biochem Biophys Res Commun)
    We further discuss emerging strategies for therapeutically targeting UBE2C, including direct inhibition, exploitation of synthetic lethal vulnerabilities, and biomarker-guided patient stratification. Collectively, this review redefines UBE2C as a systems-level regulator of ubiquitin-dependent cancer biology and highlights its potential as both a therapeutic target and a biomarker for precision oncology.
    Review • Journal
    |
    CDH1 (Cadherin 1) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    1m
    FOXM1 Signaling Network Transcriptionally Upregulates Expression of Proteins Involved in Mitotic Progression to Induce High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer. (PubMed, Int J Mol Sci)
    In light of prior work, our findings point to a FOXM1-associated 15-gene signature enriched in AR-low TNBC and associated with the high-proliferation and high-CIN phenotypes of this clinically challenging tumor type. This 15-gene set represents an actionable vulnerability with therapeutic potential for AR-low TNBC and provides a framework for rethinking how to manage highly proliferative, genomically unstable BCs.
    Journal
    |
    TP53 (Tumor protein P53) • AR (Androgen receptor) • FOXM1 (Forkhead Box M1) • PCNA (Proliferating cell nuclear antigen) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • KIF11 (Kinesin Family Member 11) • WDR5 (WD Repeat Domain 5) • CENPA (Centromere protein A) • KIF20A (Kinesin Family Member 20A) • KIF2C (Kinesin Family Member 2C) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • PSMD14 (Proteasome 26S Subunit, Non-ATPase 14) • SPDEF (SAM Pointed Domain Containing ETS Transcription Factor) • UBE2C (Ubiquitin Conjugating Enzyme E2 C) • TUBA1B (Tubulin Alpha 1b)
    |
    TP53 mutation
    2ms
    Structure-guided analysis and prediction of human E2-E3 ligase pairing specificity. (PubMed, bioRxiv)
    Here, we combine bioinformatic analysis of experimentally determined structures and AlphaFold modeling of thousands of ubiquitin-E2-E3 complexes with machine learning to predict functional E2-E3 pairings. We also introduce UbiqCore, a web resource that makes these predictions and structures broadly accessible, providing a foundation for mapping ubiquitination networks and guiding future biological and therapeutic discovery.
    Journal
    |
    UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    2ms
    SUMOylation of UBE2C facilitates hepatocellular carcinoma proliferation and invasion via the MAPK pathway. (PubMed, Transl Cancer Res)
    Rescue experiments were performed with the MAPK inhibitor trametinib...We reveal a novel oncogenic axis in which MYBL2 and SUMOylation cooperatively increase UBE2C expression and stability, promoting HCC progression via MAPK pathway activation. Targeting the MYBL2/UBE2C/MAPK axis represents a potential therapeutic strategy for treating HCC.
    Journal
    |
    PLCG2 (Phospholipase C Gamma 2) • MYBL2 (MYB Proto-Oncogene Like 2) • PRKCB (Protein Kinase C Beta) • UBE2C (Ubiquitin Conjugating Enzyme E2 C) • UBE2I (Ubiquitin Conjugating Enzyme E2 I)
    |
    Mekinist (trametinib)
    2ms
    Single-cell analysis identifies ATC-like cells driving progression in relapsed follicular thyroid carcinoma. (PubMed, Endocrinology)
    This reveals a previously unrecognized population of ATC-like cells in RFTC marked by high UBE2C expression. UBE2C contributes to FTC progression by enhancing proliferation and modulating key metabolic pathways, suggesting it as both a critical biomarker of aggressive disease and a potential therapeutic target.
    Journal
    |
    UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    2ms
    Integrative Bioinformatics and Experimental Validation Establish CCNB1 as a Potential Biomarker for Diagnosis and Prognosis in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)
    In vitro, CCNB1 knockdown triggered cell cycle arrest, thereby suppressing the proliferation of colorectal cancer cells. This study validated CCNB1 as a dual-purpose biomarker for CRC diagnosis and favorable prognosis, highlighting its potential utility in clinical management.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CDCA3 (Cell Division Cycle Associated 3) • CCNA2 (Cyclin A2) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • CDC20 (Cell Division Cycle 20) • KIF11 (Kinesin Family Member 11) • MCM4 (Minichromosome Maintenance Complex Component 4) • CCNB1 (Cyclin B1) • CDK3 (Cyclin Dependent Kinase 3) • CEP55 (Centrosomal Protein 55) • CKS2 (CDC28 Protein Kinase Regulatory Subunit 2) • CRYAB (Crystallin Alpha B) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MMP3 (Matrix metallopeptidase 3) • TPM2 (Tropomyosin 2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    3ms
    Identification of a Cuproptosis-Related Molecular Signature for Predicting Biochemical Recurrence in Prostate Cancer. (PubMed, Comb Chem High Throughput Screen)
    This study initially identified two cuproptosis-related molecules based on the expression patterns of cuproptosis-related genes. In addition, we developed a new cuproptosisrelated molecular signature with great predictive performance for BCRFS and tumor immune environment using six DERRGs (including CALML5, MMP11, UBE2C, ANPEP, TMEM59L, COMP). These findings would be conducive to a deeper cognition of the potential mechanism of cuproptosis of PCa.
    Journal • IO biomarker
    |
    MMP11 (Matrix Metallopeptidase 11) • ANPEP (Alanyl Aminopeptidase, Membrane) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)